Skip to main content
. 2021 Sep 22;26(11):925–e1918. doi: 10.1002/onco.13911

Figure 2.

Figure 2

Summary of response in patient with breast cancer. Patient with metastatic triple‐negative breast cancer received 8 prior lines of systemic therapy before enrolling in the 10 g once daily monotherapy dose cohort. Best responses of stable disease per RECIST version 1.1 and of partial response (PR) per immune‐related RECIST as evidenced by a 51% reduction in axillary mass after 4 cycles were documented. The response was progressive disease per RECIST version 1.1 criteria because of the appearance of a pulmonary nodule. The PR per immune‐related RECIST was unconfirmed because of patient hospitalization during cycle 6 for progressive disease and leptomeningeal metastases.